Lamassu BioTech, Cleveland, OH (2026)

04/14/2026

Lamassu Biotech is pleased to welcome Stephen M. Hahn, MD, as our newest board member and strategic advisor. Dr. Hahn is a nationally recognized leader in healthcare who served as the 24th Commissioner of Food and Drugs. He is the CEO of Nucleus RadioPharma, and former Chief Medical Executive at UT MD Anderson Cancer Center.

Dr. Hahn’s expertise will help advance Lamassu’s drug development process. His deep knowledge of medical and radiation oncology will assist Lamassu as we advance our genetically targeted therapy, SA53, which could be transformative in treating up to 50 percent of all cancers.

Full announcement 🔗 in the comments.

04/03/2026

Congratulations to our co-founder Dr. Rabi Hanna, chairman of Pediatric Oncology at Cleveland Clinic, who has published two articles in The New England Journal of Medicine. Dr. Hanna is an internationally recognized clinical researcher in the field of transplant and gene therapy. His mission, like ours, is to always find new and better therapies to save and improve the lives of patients with life threatening disorders through innovation and bring new treatment.

🧬 𝐂𝐑𝐈𝐒𝐏𝐑-𝐂𝐚𝐬𝟏𝟐𝐚 𝐆𝐞𝐧𝐞 𝐄𝐝𝐢𝐭𝐢𝐧𝐠 𝐨𝐟 𝐇𝐁𝐆𝟏 𝐚𝐧𝐝 𝐇𝐁𝐆𝟐 𝐏𝐫𝐨𝐦𝐨𝐭𝐞𝐫𝐬 𝐭𝐨 𝐓𝐫𝐞𝐚𝐭 𝐒𝐢𝐜𝐤𝐥𝐞 𝐂𝐞𝐥𝐥 𝐃𝐢𝐬𝐞𝐚𝐬𝐞
Dr. Hanna is the lead author in this multi-center first-in-human gene editing therapy using CRISPR/Cas12 to treat patients with severe sickle cell disease. Treatment with reni-cel led to normalization of the total hemoglobin level and an increase in the percentage of fetal hemoglobin, with no vaso-occlusive events occurring in 27 of 28 patients after infusion.
🔗 https://www.nejm.org/doi/full/10.1056/NEJMoa2415550

🩸 𝐂𝐑𝐈𝐒𝐏𝐑-𝐂𝐚𝐬𝟏𝟐𝐚 𝐆𝐞𝐧𝐞 𝐄𝐝𝐢𝐭𝐢𝐧𝐠 𝐨𝐟 𝐇𝐁𝐆𝟏 𝐚𝐧𝐝 𝐇𝐁𝐆𝟐 𝐏𝐫𝐨𝐦𝐨𝐭𝐞𝐫𝐬 𝐭𝐨 𝐓𝐫𝐞𝐚𝐭 β-𝐓𝐡𝐚𝐥𝐚𝐬𝐬𝐞𝐦𝐢𝐚
Dr. Hanna was the second author on a paper that reviewed a phase 1–2, multicenter, open-label, single-group study of reni-cel in participants 18 to 35 years of age with transfusion-dependent β-thalassemia. The participants received myeloablative conditioning with busulfan before reni-cel infusion.
Nine participants with transfusion-dependent β-thalassemia (four β0/β0 or β0/β0-like and five non–β0/β0 genotypes) received reni-cel and were included in the analysis...All the participants had neutrophil and platelet engraftment by 42 days after infusion.
🔗 https://www.nejm.org/doi/full/10.1056/NEJMoa2501277

03/26/2026

𝐂𝐚𝐥𝐥𝐢𝐧𝐠 𝐀𝐥𝐥 𝐃𝐨𝐠 🐶 𝐎𝐰𝐧𝐞𝐫𝐬!

This week, The Ohio State University College of Veterinary Medicine and Lamassu Pets, the veterinary division of Lamassu Biotech, started accepting canine patients for a new clinical trial testing a canine-specific application of RABI-767, a novel therapeutic targeting acute pancreatitis, a life-threatening condition that currently has no effective treatments in either human or veterinary medicine.
The trial, which is supported by the National Institutes of Health (NIH), involves a single injection of the drug delivered directly around the pancreas. The therapy aims to mitigate symptoms, reduce complications and protect against organ failure.
This clinical trial has the potential to make a significant impact on the field of veterinary medicine. The data collected from the canine trials will also help accelerate the development of a companion treatment for humans.

📰 Full Announcement: https://www.lamassubiotech.com/2026/03/25/ohio-state-launches-clinical-trial-for-promising-new-treatment-for-acute-pancreatitis-in-dogs/
💉 Trial Details: https://vmc.vet.osu.edu/clinical-trials-office/current-trials

03/26/2026

🛡 𝐃𝐫𝐮𝐠 𝐝𝐢𝐬𝐜𝐨𝐯𝐞𝐫𝐲 𝐚𝐥𝐰𝐚𝐲𝐬 𝐛𝐞𝐠𝐢𝐧𝐬 𝐰𝐢𝐭𝐡 𝐨𝐧𝐞 𝐪𝐮𝐞𝐬𝐭𝐢𝐨𝐧: 𝐈𝐬 𝐢𝐭 𝐬𝐚𝐟𝐞?

In oncology, 𝐭𝐨𝐱𝐢𝐜𝐢𝐭𝐲 𝐫𝐞𝐦𝐚𝐢𝐧𝐬 𝐭𝐡𝐞 #𝟏 𝐫𝐞𝐚𝐬𝐨𝐧 𝐟𝐨𝐫 𝐞𝐚𝐫𝐥𝐲-𝐬𝐭𝐚𝐠𝐞 𝐟𝐚𝐢𝐥𝐮𝐫𝐞𝐬. Analysis from the Tufts Center shows that in both 𝐏𝐡𝐚𝐬𝐞 𝐈 𝐚𝐧𝐝 𝐈𝐈𝐈, about 𝐨𝐧𝐞-𝐭𝐡𝐢𝐫𝐝 𝐨𝐟 𝐝𝐫𝐮𝐠 𝐟𝐚𝐢𝐥𝐮𝐫𝐞𝐬 𝐚𝐫𝐞 𝐝𝐮𝐞 𝐭𝐨 𝐬𝐚𝐟𝐞𝐭𝐲 𝐜𝐨𝐧𝐜𝐞𝐫𝐧𝐬.

That makes safety non-negotiable—not just a box to tick, but the foundation of sustainable drug development. It’s why at Lamassu Biotech, our investigational program 𝐒𝐀𝟓𝟑 𝐢𝐬 𝐛𝐮𝐢𝐥𝐭 𝐰𝐢𝐭𝐡 𝐚 “𝐬𝐚𝐟𝐞𝐭𝐲-𝐟𝐢𝐫𝐬𝐭” 𝐩𝐡𝐢𝐥𝐨𝐬𝐨𝐩𝐡𝐲 𝐟𝐫𝐨𝐦 𝐝𝐚𝐲 𝐨𝐧𝐞.

We embed rigorous early screening, risk assessment, and safety analytics into every stage—from molecular design to preclinical validation—to minimize risk and maximize patient confidence.

𝐀𝐭 𝐋𝐚𝐦𝐚𝐬𝐬𝐮 𝐁𝐢𝐨𝐭𝐞𝐜𝐡, 𝐬𝐚𝐟𝐞𝐭𝐲 𝐢𝐬𝐧’𝐭 𝐚𝐧 𝐚𝐟𝐭𝐞𝐫𝐭𝐡𝐨𝐮𝐠𝐡𝐭—𝐢𝐭’𝐬 𝐭𝐡𝐞 𝐬𝐭𝐚𝐫𝐭𝐢𝐧𝐠 𝐩𝐨𝐢𝐧𝐭.

⚠️ Disclaimer: SA53 is investigational. Visit LamassuBiotech.com for updates on RABI-767 and other novel therapies under development.
📚 Source: Hay M et al., Nat Biotechnol. 2014;

03/24/2026

🔍 𝐏𝐚𝐧𝐜𝐫𝐞𝐚𝐭𝐢𝐭𝐢𝐬: 𝐬𝐞𝐩𝐚𝐫𝐚𝐭𝐢𝐧𝐠 𝐦𝐲𝐭𝐡 𝐟𝐫𝐨𝐦 𝐫𝐞𝐚𝐥𝐢𝐭𝐲.

Myth 1: “Pancreatitis = alcohol only.”
👉 Reality: Gallstones are actually the leading cause, responsible for ~40–70% of cases.

Myth 2: “It’s always mild.”
👉 Reality: Severe pancreatitis can be life-threatening, with complications that require intensive care.

At Lamassu Biotech, 𝐨𝐮𝐫 𝐢𝐧𝐯𝐞𝐬𝐭𝐢𝐠𝐚𝐭𝐢𝐨𝐧𝐚𝐥 𝐩𝐫𝐨𝐠𝐫𝐚𝐦 𝐑𝐀𝐁𝐈-𝟕𝟔𝟕 𝐢𝐬 𝐟𝐨𝐜𝐮𝐬𝐞𝐝 𝐨𝐧 𝐚𝐝𝐝𝐫𝐞𝐬𝐬𝐢𝐧𝐠 𝐭𝐡𝐞 𝐮𝐧𝐝𝐞𝐫𝐥𝐲𝐢𝐧𝐠 𝐦𝐞𝐜𝐡𝐚𝐧𝐢𝐬𝐦𝐬 𝐨𝐟 𝐚𝐜𝐮𝐭𝐞 𝐩𝐚𝐧𝐜𝐫𝐞𝐚𝐭𝐢𝐭𝐢𝐬 — because the myths don’t capture the true burden of this disease.

⚠️ Disclaimer: RABI-767 is investigational. Visit LamassuBiotech.com for updates on RABI-767 and other novel therapies under development.
📚 Source: Yadav D, Lowenfels AB. N Engl J Med. 2013.

03/19/2026

🔬 𝐇𝐨𝐰 𝐝𝐨𝐞𝐬 𝐚 𝐦𝐨𝐥𝐞𝐜𝐮𝐥𝐞 𝐛𝐞𝐜𝐨𝐦𝐞 𝐚 𝐝𝐫𝐮𝐠 𝐜𝐚𝐧𝐝𝐢𝐝𝐚𝐭𝐞?

The journey is long and selective:

1️⃣ Library screening – identifying molecules with activity.
2️⃣ Refinement – optimizing for potency, selectivity, and properties.
3️⃣ Preclinical testing – evaluating biology, pharmacology, and safety.
4️⃣ Candidate nomination – choosing the molecule with the best profile.
But the path is tough: fewer than 10% of preclinical oncology drugs ever reach approval.

At Lamassu Biotech, our 𝐧𝐨𝐯𝐞𝐥 𝐠𝐞𝐧𝐞𝐭𝐢𝐜𝐚𝐥𝐥𝐲-𝐭𝐚𝐫𝐠𝐞𝐭𝐞𝐝 𝐒𝐀𝟓𝟑 𝐭𝐡𝐞𝐫𝐚𝐩𝐲 reflects this disciplined process. Built on science, refined through data, designed for patients.

⚠️ Disclaimer: SA53 is investigational. Follow us for updates on our pipeline.
📚 Source: Wong CH et al., Clin Transl Sci. 2019.

03/17/2026

🐾 Pancreatitis doesn’t just affect humans.

Dogs and cats also develop acute pancreatitis. Yet across veterinary medicine, treatment options remain limited — largely supportive care only.

This mirrors the challenge in human medicine, where no approved drug exists to address the underlying biology of the disease. In collaboration with The Ohio State University College of Veterinary Medicine, Lamassu Pets is advancing RABI-767, an investigational program designed to target the processes at the root of pancreatitis

Because whether in humans or animals, the unmet need is clear — and research must continue.

⚠️ Disclaimer: RABI-767 is investigational. Visit LamassuBiotech.com for updates on RABI-767 and other novel therapies under development.

📚 Source: Watson P. J Small Anim Pract. 2015

03/12/2026

🧬 𝐖𝐡𝐲 𝐢𝐬 𝐩𝟓𝟑 𝐜𝐚𝐥𝐥𝐞𝐝 𝐭𝐡𝐞 “𝐠𝐮𝐚𝐫𝐝𝐢𝐚𝐧 𝐨𝐟 𝐭𝐡𝐞 𝐠𝐞𝐧𝐨𝐦𝐞”?

Because it sits at the heart of the cell’s defense — protecting against DNA errors, uncontrolled growth, and malignant transformation. When functioning properly, p53:
- Arrests the 𝐜𝐞𝐥𝐥 𝐜𝐲𝐜𝐥𝐞 upon detecting DNA damage, granting time for repair.
- 𝐈𝐧𝐢𝐭𝐢𝐚𝐭𝐞𝐬 𝐚𝐩𝐨𝐩𝐭𝐨𝐬𝐢𝐬 when damage is irreparable.
- Regulates 𝐃𝐍𝐀 𝐫𝐞𝐩𝐚𝐢𝐫 𝐩𝐚𝐭𝐡𝐰𝐚𝐲𝐬, 𝐬𝐞𝐧𝐞𝐬𝐜𝐞𝐧𝐜𝐞, 𝐦𝐞𝐭𝐚𝐛𝐨𝐥𝐢𝐬𝐦, 𝐢𝐦𝐦𝐮𝐧𝐞 𝐬𝐮𝐫𝐯𝐞𝐢𝐥𝐥𝐚𝐧𝐜𝐞, 𝐚𝐧𝐝 𝐞𝐯𝐞𝐧 𝐚𝐧𝐠𝐢𝐨𝐠𝐞𝐧𝐞𝐬𝐢𝐬.

But the reality is sobering: 𝐓𝐏𝟓𝟑 𝐢𝐬 𝐭𝐡𝐞 𝐦𝐨𝐬𝐭 𝐟𝐫𝐞𝐪𝐮𝐞𝐧𝐭𝐥𝐲 𝐦𝐮𝐭𝐚𝐭𝐞𝐝 𝐠𝐞𝐧𝐞 𝐢𝐧 𝐜𝐚𝐧𝐜𝐞𝐫 — 𝐟𝐨𝐮𝐧𝐝 𝐢𝐧 𝐨𝐯𝐞𝐫 𝟓𝟎% 𝐨𝐟 𝐡𝐮𝐦𝐚𝐧 𝐭𝐮𝐦𝐨𝐫𝐬.

Despite decades of research, restoring p53 function remains a formidable challenge. However, recent breakthroughs provide renewed optimism:
- A comprehensive mutational scan using CRISPR covering over 9,000 TP53 variants has pinpointed specific mutations that may be 𝐩𝐡𝐚𝐫𝐦𝐚𝐜𝐨𝐥𝐨𝐠𝐢𝐜𝐚𝐥𝐥𝐲 𝐫𝐞𝐚𝐜𝐭𝐢𝐯𝐚𝐭𝐚𝐛𝐥𝐞, opening new avenues for precision therapy.
- Insights into p53’s structural fragility — especially its evolutionarily optimized but unstable DNA-binding domain — reveal 𝐰𝐡𝐲 𝐢𝐭'𝐬 𝐛𝐨𝐭𝐡 𝐡𝐢𝐠𝐡𝐥𝐲 𝐚𝐝𝐚𝐩𝐭𝐢𝐯𝐞 𝐚𝐧𝐝 𝐩𝐚𝐫𝐭𝐢𝐜𝐮𝐥𝐚𝐫𝐥𝐲 𝐯𝐮𝐥𝐧𝐞𝐫𝐚𝐛𝐥𝐞 𝐭𝐨 𝐦𝐮𝐭𝐚𝐭𝐢𝐨𝐧 — knowledge that’s valuable for drug design.

At Lamassu BioTech, our novel genetically-targeted therapy SA53 is built to respect this complexity. By 𝐭𝐚𝐫𝐠𝐞𝐭𝐢𝐧𝐠 𝐭𝐡𝐞 𝐌𝐃𝐌𝟐–𝐩𝟓𝟑 𝐚𝐱𝐢𝐬, 𝐰𝐞 𝐚𝐢𝐦 𝐭𝐨 𝐫𝐞𝐚𝐰𝐚𝐤𝐞𝐧 𝐩𝟓𝟑’𝐬 𝐠𝐮𝐚𝐫𝐝𝐢𝐚𝐧 𝐫𝐨𝐥𝐞 and unlock its power to suppress tumors.

𝐒𝐜𝐢𝐞𝐧𝐜𝐞 𝐞𝐯𝐨𝐥𝐯𝐞𝐬. 𝐒𝐨 𝐝𝐨𝐞𝐬 𝐨𝐮𝐫 𝐰𝐨𝐫𝐤.

⚠️ Disclaimer: SA53 is investigational. Visit LamassuBiotech.com for updates on SA53 and other novel therapies under development..
📚 Sources: Levine AJ et al., Nat Rev Cancer 2020

03/10/2026

⏳ 𝐈𝐧 𝐚𝐜𝐮𝐭𝐞 𝐩𝐚𝐧𝐜𝐫𝐞𝐚𝐭𝐢𝐭𝐢𝐬, 𝐭𝐢𝐦𝐞 𝐦𝐚𝐭𝐭𝐞𝐫𝐬.

For many patients, an episode of AP begins suddenly — severe abdominal pain brings them to the 𝐞𝐦𝐞𝐫𝐠𝐞𝐧𝐜𝐲 𝐫𝐨𝐨𝐦 (𝐄𝐑). While some cases remain mild, the disease can escalate quickly:
➡️ 𝐃𝐚𝐲 𝟎 → 𝐄𝐑
➡️ 𝐇𝐨𝐬𝐩𝐢𝐭𝐚𝐥𝐢𝐳𝐚𝐭𝐢𝐨𝐧 for monitoring and supportive care
➡️ 𝐈𝐂𝐔 𝐚𝐝𝐦𝐢𝐬𝐬𝐢𝐨𝐧 for patients who progress to severe disease

📊 Roughly 𝟏 𝐢𝐧 𝟓 𝐩𝐚𝐭𝐢𝐞𝐧𝐭𝐬 (≈𝟐𝟎%) 𝐰𝐢𝐭𝐡 𝐚𝐜𝐮𝐭𝐞 𝐩𝐚𝐧𝐜𝐫𝐞𝐚𝐭𝐢𝐭𝐢𝐬 𝐝𝐞𝐯𝐞𝐥𝐨𝐩 𝐚 𝐬𝐞𝐯𝐞𝐫𝐞 𝐟𝐨𝐫𝐦 𝐫𝐞𝐪𝐮𝐢𝐫𝐢𝐧𝐠 𝐢𝐧𝐭𝐞𝐧𝐬𝐢𝐯𝐞 𝐜𝐚𝐫𝐞, often with life-threatening organ failure.

Despite decades of research, 𝐭𝐫𝐞𝐚𝐭𝐦𝐞𝐧𝐭 𝐫𝐞𝐦𝐚𝐢𝐧𝐬 𝐬𝐮𝐩𝐩𝐨𝐫𝐭𝐢𝐯𝐞 𝐨𝐧𝐥𝐲 — fluids, pain management, and vigilant observation. 𝐍𝐨 𝐝𝐫𝐮𝐠 𝐡𝐚𝐬 𝐞𝐯𝐞𝐫 𝐛𝐞𝐞𝐧 𝐚𝐩𝐩𝐫𝐨𝐯𝐞𝐝 to address the underlying biology of this condition.

At Lamassu BioTech, we are advancing 𝐑𝐀𝐁𝐈-𝟕𝟔𝟕, 𝐚𝐧 𝐢𝐧𝐯𝐞𝐬𝐭𝐢𝐠𝐚𝐭𝐢𝐨𝐧𝐚𝐥 𝐭𝐡𝐞𝐫𝐚𝐩𝐲 designed to target the root processes that drive severe acute pancreatitis. Our goal is to change the trajectory — so that fewer patients move from the ER to the ICU.

⚠️ Disclaimer: RABI-767 is investigational. Visit LamassuBiotech.com for updates on RABI-767 and other novel therapies under development.
📚 Source: Tenner S et al., Am J Gastroenterol. 2013.

03/05/2026

🧬 𝐩𝟓𝟑 𝐢𝐬 𝐨𝐧𝐞 𝐨𝐟 𝐭𝐡𝐞 𝐦𝐨𝐬𝐭 𝐬𝐭𝐮𝐝𝐢𝐞𝐝 𝐠𝐞𝐧𝐞𝐬 𝐢𝐧 𝐜𝐚𝐧𝐜𝐞𝐫 𝐛𝐢𝐨𝐥𝐨𝐠𝐲 — 𝐛𝐮𝐭 𝐚𝐥𝐬𝐨 𝐨𝐧𝐞 𝐨𝐟 𝐭𝐡𝐞 𝐦𝐨𝐬𝐭 𝐦𝐢𝐬𝐮𝐧𝐝𝐞𝐫𝐬𝐭𝐨𝐨𝐝.

Let’s bust a few myths:
𝐌𝐲𝐭𝐡 𝟏: “𝐩𝟓𝟑 𝐢𝐬 𝐣𝐮𝐬𝐭 𝐨𝐧𝐞 𝐠𝐞𝐧𝐞.”
👉 Reality: It regulates a network of pathways controlling cell cycle, DNA repair, apoptosis, and more.
𝐌𝐲𝐭𝐡 𝟐: “𝐀𝐥𝐥 𝐜𝐚𝐧𝐜𝐞𝐫𝐬 𝐥𝐨𝐬𝐞 𝐩𝟓𝟑.”
👉 Reality: Some retain wild-type p53, but it’s silenced by regulators like MDM2.

𝐒𝐜𝐢𝐞𝐧𝐜𝐞 𝐞𝐯𝐨𝐥𝐯𝐞𝐬. 𝐒𝐨 𝐝𝐨𝐞𝐬 𝐨𝐮𝐫 𝐰𝐨𝐫𝐤. That’s why at Lamassu BioTech, we are advancing 𝐒𝐀𝟓𝟑, 𝐨𝐮𝐫 𝐧𝐨𝐯𝐞𝐥 𝐠𝐞𝐧𝐞𝐭𝐢𝐜𝐚𝐥𝐥𝐲-𝐭𝐚𝐫𝐠𝐞𝐭𝐞𝐝 𝐭𝐡𝐞𝐫𝐚𝐩𝐲 𝐭𝐚𝐫𝐠𝐞𝐭𝐢𝐧𝐠 𝐭𝐡𝐞 𝐌𝐃𝐌𝟐–𝐩𝟓𝟑 𝐚𝐱𝐢𝐬.

⚠️ Disclaimer: SA53 is investigational. Visit LamassuBiotech.com for updates on SA53 and other novel therapies under development.
📚 Source: Levine AJ. Nat Rev Cancer. 2020.

03/03/2026

🚀 𝐍𝐨𝐯𝐞𝐥𝐭𝐲 𝐢𝐧 𝐝𝐫𝐮𝐠 𝐝𝐞𝐯𝐞𝐥𝐨𝐩𝐦𝐞𝐧𝐭 𝐢𝐬𝐧’𝐭 𝐣𝐮𝐬𝐭 𝐚𝐛𝐨𝐮𝐭 𝐬𝐩𝐞𝐞𝐝 — 𝐢𝐭’𝐬 𝐚𝐛𝐨𝐮𝐭 𝐝𝐢𝐫𝐞𝐜𝐭𝐢𝐨𝐧.

For decades, acute pancreatitis (AP) has remained a 𝐭𝐡𝐞𝐫𝐚𝐩𝐞𝐮𝐭𝐢𝐜 𝐝𝐞𝐬𝐞𝐫𝐭:
- Hundreds of thousands of hospitalizations each year.
- Severe AP mortality up to 20–40%.

𝟎 𝐚𝐩𝐩𝐫𝐨𝐯𝐞𝐝 𝐝𝐫𝐮𝐠𝐬 𝐰𝐨𝐫𝐥𝐝𝐰𝐢𝐝𝐞.

That is why 𝐑𝐀𝐁𝐈-𝟕𝟔𝟕 is different:
🧬 𝐌𝐞𝐜𝐡𝐚𝐧𝐢𝐬𝐦: RABI-767 is a novel small-molecule 𝐥𝐢𝐩𝐚𝐬𝐞 𝐢𝐧𝐡𝐢𝐛𝐢𝐭𝐨𝐫. By blocking the breakdown of triglycerides into toxic free fatty acids, it aims to address the 𝐫𝐨𝐨𝐭 𝐦𝐞𝐜𝐡𝐚𝐧𝐢𝐬𝐦 𝐨𝐟 𝐨𝐫𝐠𝐚𝐧 𝐟𝐚𝐢𝐥𝐮𝐫𝐞 in severe AP.
📈 𝐂𝐥𝐢𝐧𝐢𝐜𝐚𝐥 𝐦𝐨𝐦𝐞𝐧𝐭𝐮𝐦:
- Licensed from Mayo Clinic, advancing with translational science at its core.
- 𝐅𝐚𝐬𝐭 𝐓𝐫𝐚𝐜𝐤 𝐝𝐞𝐬𝐢𝐠𝐧𝐚𝐭𝐢𝐨𝐧 𝐛𝐲 𝐭𝐡𝐞 𝐅𝐃𝐀 (𝟐𝟎𝟐𝟒).
- 𝐂𝐮𝐫𝐫𝐞𝐧𝐭𝐥𝐲 𝐢𝐧 𝐏𝐡𝐚𝐬𝐞 𝟐𝐚 𝐜𝐥𝐢𝐧𝐢𝐜𝐚𝐥 𝐞𝐯𝐚𝐥𝐮𝐚𝐭𝐢𝐨𝐧.

This is not about treating symptoms — it’s about rethinking pancreatitis at its origin. At Lamassu BioTech, our mission is to turn decades of unmet need into a future with real therapeutic options.

⚠️ Disclaimer: RABI-767 is investigational. Visit LamassuBiotech.com for updates on RABI-767 and other novel therapies under development.
📚 Sources: Arrivo BioVentures, FDA Fast Track announcement 2024; Forsmark CE, N Engl J Med. 2016.

02/27/2026

Success comes from having a sound understanding of the industry's landscape and what differentiates your company from your competitors. That was the message from biotech leaders during this week's "Catalyzing Cancer Innovation" panel discussion, hosted by I am Biotech's BIOPartnering™. Lamassu BioTech CEO Gabi Hanna MD shared his insights on the challenges and opportunities for companies looking for success in 2026 alongside Rodman & Renshaw Senior Biotechnology Analyst Michael G King Jr, Bantam Pharmaceutical CEO Michael Stocum, Creatv MicroTech, Inc. CBO Ron Baker, and Oncode Accelerator Business Development Manager Federica Frati.

Lamassu BioTech

04/14/2026

04/03/2026

03/26/2026

03/26/2026

03/24/2026

03/19/2026

03/17/2026

03/12/2026

03/10/2026

03/05/2026

03/03/2026

02/27/2026

Address

Website

Alerts

Shortcuts

Share

Category